JCRC – A Centre of Excellence
C abotegravir A nd R ilpivirine: E fficacy and S afety Study
The CARES trial is a phase 3b, randomized, open label clinical trial evaluating the efficacy, safety, and tolerability of switching to cabotegravir long-acting (CAB LA) plus rilpivirine long-acting (RPV LA) in virologically suppressed HIV-1 infected adults on oral antiretrovirals in Sub-Saharan Africa.
The trial is sponsored by the Joint Clinical Research Centre (JCRC), Uganda and funded by Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), involving eight sites in Uganda, Kenya and South Africa.
JCRC – A Centre of Excellence